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Abstract
Severe coronavirus disease 2019 (COVID-19) as a respiratory tract infection has been noted to
be a causative agent for acute respiratory distress syndrome, shock, and multiple organ failure.
It is also being suggested that COVID-19 results in serious systemic coagulopathies similar to
disseminated intravascular coagulation. We describe a case of severe arterial thrombosis
induced by COVID-19 infection along with its pathological implications.

Categories: Internal Medicine, Epidemiology/Public Health, Hematology
Keywords: covid 19, limb ischemia, hematology-oncology, world pandemic

Introduction
Coronavirus disease 2019 (COVID-19) has been declared a worldwide pandemic and is giving
rise to a myriad of coagulation abnormalities along with the constitutional and respiratory tract
symptoms [1]. The most common coagulation abnormalities noted so far include thrombotic
events in major venous vessels, with various derangements in inflammatory markers especially
D-dimers and fibrinogen [2]. In this case report, we describe an interesting clinical scenario of
arterial thrombus formation in a COVID-19 patient despite being on full anti-coagulation,
resulting in limb-threatening limb ischemia.

Case Presentation
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A 58-year-old male with a pertinent past medical history of dyslipidemia initially presented to
the hospital due to acute shortness of breath and subjective fever for the past week. On
presentation, he was swabbed for novel coronavirus, which resulted as positive. For the first
five days, he was monitored on the regular medical floor for his oxygen requirements, which
fluctuated between 2 and 3 liters on the nasal cannula. He was initiated on hydroxychloroquine
and azithromycin for five days, and his progression of inflammatory markers was trending
every 48 hours (Table 1).
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Inflammatory Markers

Results

C-reactive protein

25.23

Lactose dehydrogenase

558

D-dimers

15,653

Procalcitonin

0.17

Ferritin

1,311

Fibrinogen

312

TABLE 1: Inflammatory markers on admission

On the fifth day of admission, the patient’s oxygen requirement worsened to the point that he
had to be transitioned to a non-rebreather mask on 15 liters. His other vital signs included a
blood pressure of 130/75 mm Hg, respiratory rate of 22 breaths per minute, temperature of 99.4
degrees Celsius, and pulse oxygenation ranging from 90% to 94%. He was transferred to the
critical care unit for closer monitoring. He was initiated on intravenous corticosteroids and
interleukin (IL) 1 inhibitor anakinra. On the seventh day, he started complaining about
paleness and cold left lower extremity as compared to the right side. On examination, there
were no motor or sensory deficits; however, pulses were detectable only on Doppler ultrasound
(Figure 1). Urgent vascular surgery evaluation was conducted, and the bilateral arterial duplex
was performed, which demonstrated normal arterial flow. The patient, however, was switched
to therapeutic low molecular weight heparin (LMWH) given the high suspicion for
prothrombotic state associated with cytokine release syndrome.
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FIGURE 1: Arterial ultrasound of the left lower extremity with
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waveforms
The arterial ultrasound of the left lower extremity did not show any occlusions.
CFA, common femoral artery; SFA Prox, superficial femoral artery proximal; SFA Mid, superficial
femoral artery mid; SFA Dis, superficial femoral artery distal; Pop, popliteal; PTA, posterior tibial
artery; Peron, peroneal; ATA, anterior tibial artery

His oxygen requirements were successfully titrated down to 6 liters by the 10th day of
hospitalization; however, he continued to complain about his left cold foot, which gradually
progressed to develop cyanosis. The patient at this time was switched to intravenous heparin
drip in consideration of unstable peripheral vascular disease. With no improvement noted in
his cyanosis, CT angiogram was obtained, which demonstrated filling defects in the main left
femoral artery suspicious of thrombus (Figure 2). Decreased blood flow was also noted in the
left popliteal, posterior tibial, peroneal, and anterior tibial arteries.
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FIGURE 2: CT angiogram of the lower extremities
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The arrowhead showing reduced blood flow with blockage in the arterial vessels of the left lower
extremity.

Heparin drip was continued and aspirin 81 milligrams was added in the regimen. Despite being
on full anticoagulation, the patient was developing arterial thromboses, which prompted
hematology evaluation for hypercoagulable screening. Peripheral smear was also performed,
which did not reveal any schistocytes; the red blood cells, leukocytes, and platelets
demonstrated normal features.
Extensive blood workup including genetic studies was obtained, which are summarized in Table
2. The mildly elevated anticardiolipin immunoglobulin M was considered secondary to
inflammation and deemed non-specific. Ultimately, vascular surgery was performed, with
angioplasty as limb salvage therapy in the femoral, popliteal, and tibial arteries. The revascularization was followed with below-the-ankle amputation of the necrotic dead tissue.

Tests and Markers

Results

Beta 2 glycoprotein

Negative

Anticardiolipin immunoglobulin G

Negative

Anticardiolipin immunoglobulin M

Slightly positive

Anti-nuclear and anti-double-stranded DNA antibodies

Negative

JAK 2-V617 mutation

Negative

CALR gene mutation

Negative

Flow cytometry

Normal

MPL gene mutation

Negative

JAK 2 exon mutation

Negative

Erythropoietin

Normal

TABLE 2: Gene mutation and markers for hypercoagulability profile

Discussion
The inflammatory process has been described to be closely interlinked with and resulting in a
pro-thrombotic state in humans in several studies. When the inflammatory process damages
the endothelial linings of the macro- and microvasculature, it disrupts the normal
antithrombotic and anti-inflammatory mechanisms, resulting in unchecked activation of the
thrombotic cascade. [1] COVID-19 was declared a worldwide pandemic by the World Health
Organization on March 11, 2020. While many patients develop mild-to-moderate symptoms
(fever, fatigue, myalgia, headache, diarrhea, dry cough, and dyspnea), several patients have
been described to have severe systemic disease, resulting in a myriad of coagulation
abnormalities [2].
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The suggested mechanism through which SARS-CoV-2 (severe acute respiratory syndrome
coronavirus 2) causes the systemic disease is through angiotensin-converting enzyme 2 (ACE-2)
receptors. The SARS-CoV-2 proteins infect human cells through ACE-2 receptors, which are
expressed in various degrees in alveolar epithelial cells, large and small arterial endothelial
cells, small intestinal epithelial cells, immune tissues, and various other types of
cells [3]. SARS-CoV-2 directly attacks vascular endothelial cells and activates the coagulation
cascade after causing endothelial injury. This pathologic insult is suggested to result in
excessive cytokine release and storm from activating of widespread coagulation factors while
inhibiting fibrinolysis causing extensive thrombosis similar to disseminated intravascular
coagulation. IL-6 is a key factor in SARS-CoV-2 induced inflammatory storm. While IL-6 can
stimulate the liver to synthesize fibrinogen and thrombopoietin, it also upregulates the
expression of vascular endothelial growth factor to disrupt the stability of vascular barrier and
stimulate monocytes to express more tissue factors, thereby activating the extrinsic pathway of
coagulation [4]. These coagulation abnormalities along with elevated D-dimers are likely
indicators for higher mortality predisposing the patients to a variety of ischemic and
thrombotic events [5].
Various elevated markers including D-dimers, partial thromboplastin time (PTT), prothrombin
time (PT), fibrinogen, fibrin degradation products (FDP), and IL- 6 have been described to
determine the progression of sepsis-induced prothrombotic disease secondary to SARS-CoV2 [6]. It is interesting to note that although several studies have shown severe thrombotic
events associated with SARS-Cov-2 sepsis, limited data are available to suggest uncontrolled
bleeding diathesis caused by COVID-19 except for intracerebral hemorrhages [7]. A small
retrospective analysis of 20 critically ill COVID-19 patients was conducted who had different
degrees of limb ischemia and variable re-vascularization success [8]. Our clinical scenario was
unique in describing the development of acute limb ischemia despite being on full therapeutic
anticoagulation with LMWH. Although the initial arterial Doppler ultrasound of the lower
extremities failed to show any thrombosis, our patient was initiated on 1 mg/kg enoxaparin
twice daily. With no significant improvement noted, a CT angiogram was performed, which
demonstrated several filling defects.
As not enough data are available to confirm COVID-19 as being the culprit for arterial
thrombosis, it mandated a hematology-oncology evaluation to rule out rare causes of
thrombosis including malignancy. Extensive workup including gene mutations and flow
cytometry was performed and resulted in negative. The patient finally underwent limb salvage
therapy through angioplasty with below-the-ankle amputation of the gangrenous tissue [9,10].
The role of anticoagulants in preventing thrombotic complications and improving the overall
prognosis in COVID-19 has not been clearly established. Tang et al. in their study of 499
patients with COVID-19, out of which 99 patients received LMWH therapy, reported that
anticoagulant therapy mainly with LMWH appears to be associated with better outcomes in
severe COVID-19 patients [11]. It was interesting to note that despite being on full
anticoagulation with LMWH and later with unfractionated heparin, our patient’s gangrene
continued to worsen, ultimately requiring vascular intervention.
There is supporting evidence available for using prophylactic anticoagulation for venous
thromboembolism; however, it is unclear whether prophylactic or full anticoagulation will be
beneficial for arterial thrombosis caused by COVID-19 [12]. In current medical practice, the
patients with viable tissue and marginally threatened limb undergo vascular intervention for
arterial thrombolysis and thrombectomy. Limbs with irreversible ischemia require amputation,
as in our clinical case.

Conclusions
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The subject of SARS-CoV-2 induced coagulation abnormalities leading to thrombotic
complications requires further large-scale studies thoroughly at the molecular level. For
critically ill patients with COVID-19, special attention should be paid to abnormal coagulation
dysfunction and microcirculatory disorders. Prophylactic anticoagulation has been reported to
be beneficial for venous thromboembolism induced by COVID-19; however, arterial
thromboembolic events as seen in our patient would require prompt vascularization due to
anticoagulation failure.
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